In order to assess expression of MCL1 in prostatic tissue and to validate MCL1 as a potential target for treatment of PCa we performed immunohistochemistry on tissue specimens from treatment-naïve prostate cancer (tnPCa) patients who underwent radical prostatectomy (Fig. 1A). This evidence concerns the gene MCL1 and posterior cortical atrophy.